Edwards Lifesciences CorpEW

NYSEHealthcareOrthopedic, Prosthetic & Surgical Appliances & Supplies
Price (close)
$85.73
Market cap
$49.4B
P/E
49.2x
Revenue (TTM)
$6.5B
Net income
$1.0B
Dividend yield
—
1-year total return
13.9%
Net margin
15.4%
Revenue growth
14.6%
Debt / equity
0.06x

What Edwards Lifesciences Corp does.

Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades. Since our founder, Miles “Lowell” Edwards, first dreamed of using engineering to address diseases of the human heart, we have steadily built a company on the premise of imagining, building, and realizing a better future for patients.

Our innovative work encompasses both surgical and transcatheter therapies. In addition, our unique portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a broad set of treatment options to serve the many diverse and complex patients in need. Edwards remains committed to its strategy of transformative product innovation, high-quality, expansive clinical evidence to support approvals and adoption, as well as comprehensive support to ensure excellent real-world patient outcomes.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$4.4B$5.2B$4.5B$5.0B$5.4B$6.1B
Net income—$1.5B$1.5B$1.4B$4.2B$1.1B
Free cash flow$647.3M$1.4B$973.6M$642.8M$289.9M$1.3B

More on EW.

Figures from Edwards Lifesciences Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.